Iran has won US approval to transfer funds for coronavirus vaccines from overseas, the central bank chief said on Thursday, as its daily death toll fell to a three-month low.
Central Bank governor Abdolnaser Hemmati said an Iranian bank had received backing from the US Treasury's Office of Foreign Assets Control to transfer the money to a Swiss bank to pay for the vaccines.
"They (Americans) have put sanctions on all our banks. They accepted this one case under the pressure of world public opinion," Hemmati told state TV.
Follow Israel Hayom on Facebook and Twitter
There was no immediate US reaction to Hemmati's remarks.
Hemmati said Iran would pay around $244 million for initial imports of 16.8 million doses of vaccines from COVAX, a multi-agency group dedicated to assuring fair access to vaccines for low- and middle-income countries.
Iranian officials have said repeatedly that US sanctions are preventing them from making payments to COVAX, to which some 190 economies have signed up.
Iran's Shifa Pharmed began registering volunteers this week for human trials of the country's first domestic COVID-19 vaccine candidate, Iranian media reported, as a factional dispute appeared to be brewing over the use of imports.
"We do not recommend injecting foreign coronavirus vaccines to the personnel of the Revolutionary Guards and the basij (voluntary militia)," Iranian news outlets quoted Mohammed Reza Naqdi, a deputy head of the hardline Revolutionary Guards, as saying.
Health Ministry spokeswoman Sima Sadat Lari told state TV earlier that 152 people had died of COVID-19 in Iran in the past 24 hours, the lowest number since Sept. 18, taking total deaths to 54,308 in the worst-affected country in the Middle East.
The fall in deaths comes after more than a month of night traffic curfews and other restrictions in major cities. Police said 96,000 fines were issued nationwide on Wednesday for drivers breaking the curfew.
Officials have cautioned that the danger of a resurgence in infections looms large.
Subscribe to Israel Hayom's daily newsletter and never miss our top stories!
